BioSpace News Archive

VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, and Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced they have entered into a definitive merger agreement.

Genprex, today announced that data highlighting the potential of Genprex’s gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 2023 in Berlin, Germany.

Xeris Biopharma Holdings, Inc. today announced that the Company will release its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, March 8, 2023.

Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors.

NeoGenomics, Inc. today announced fourth quarter and full year 2022 results for the period ended December 31, 2022.

GATC Health Corp, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), welcomes Lin Yu Ph.D., to its Board of Directors.

Areteia Therapeutics today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development.

scPharmaceuticals Inc. today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the Cowen 43rd Annual Health Care Conference, on Wednesday, March 8 at 10:30 am ET in Boston.

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a general business update.

Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) announced today that its Phase II clinical study (“Study II”) interim data was recently presented at the American Society of Clinical Oncology (“ASCO”) Genito Urinary (“GU”) Cancer Symposium via a moderated poster presentation.